http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Hyun Kuk,Hong, Young Joon,Jeong, Myung Ho,Kim, Weon,Kim, Sung Soo,Ko, Jum Suk,Lee, Min Goo,Sim, Doo Sun,Park, Keun Ho,Yoon, Nam Sik,Yoon, Hyun Ju,Kim, Kye Hun,Park, Hyung Wook,Kim, Ju Han,Ahn, Yo The Korean Association of Internal Medicine 2011 The Korean Journal of Internal Medicine Vol.26 No.1
<P><B>Background/Aims</B></P><P>Carvedilol is an antioxidant that inhibits smooth muscle cell proliferation and migration. The aim of this study was to investigate the beneficial effects of carvedilol-loaded stents on 2-year clinical outcomes after stent implantation in patients with coronary artery disease.</P><P><B>Methods</B></P><P>We performed a prospective trial with male subjects to compare the safety and effects of carvedilol-loaded BiodivYsio® stents implanted into 20 patients with those of bare-metal BiodivYsio® stents implanted into 21 patients for de novo coronary lesions. The primary end point was the degree of neointimal hyperplasia, which was measured by intravascular ultrasound (IVUS) 6 months after the procedure; the secondary end point was major adverse cardiac events (MACE) at 2 years after implantation. All carvedilol and control stents were deployed successfully.</P><P><B>Results</B></P><P>A 2-year follow-up was completed for 19 patients (95%) in the carvedilol stent group and 20 patients (95%) in the control stent group. IVUS showed a trend toward a larger luminal area (6.86 ± 2.59 vs. 5.47 ± 1.52 mm<SUP>2</SUP>, <I>p</I> = 0.267), smaller neointimal area (1.34 ± 0.70 vs. 2.40 ± 1.73 mm<SUP>2</SUP>, <I>p</I> = 0.18), and reduced net decrease in luminal area (-0.78 ± 0.97 vs. -1.89 ± 1.78 mm<SUP>2</SUP>, <I>p</I> = 0.106) in the carvedilol stent group compared with the control stent group, respectively. There were no significant differences in the incidence of MACE (10.5 vs. 30.0%, respectively, <I>p</I> = 0.132) between the groups at 2 years after stent implantation. Stent thrombosis did not occur in either group after 2 years.</P><P><B>Conclusions</B></P><P>The carvedilol-loaded stents tended to inhibit neointimal hyperplasia without the occurrence of cardiac death, myocardial infarction, or stent thrombosis at 2-year follow-up.</P>
Undifferentiated endometrial sarcoma mimicking submucosal myoma: A case report
( Gun Sik Park ),( Hyun Sik Youm ),( Soo Jin Song ),( Byeung Jum Kim ),( Mi Eun Jung ),( Sang Chill Kwon ),( Sang Kook Kim ),( Yu Kyung Cho ),( Ja Sung Koo ),( Hwal Woong Kim ),( Hwa Sook Moon ) 대한산부인과학회 2012 대한산부인과학회 학술대회 Vol.98 No.-
Endometrial stromal tumors are the second most common uterine sarcomas. They are divided into three types; endometrial stromal nodule, endometrial stromal sarcoma (ESS), and undifferentiated endometrial sarcoma (UES). UES is much less common than ESS. And it has a much more aggressive clinical course and poorer prognosis than ESS. Case: A 47-year-old woman presented to our hospital with a 4-month history of irregular vaginal bleeding. TVUS revealed a vascularized mass mimicking submucosal myoma in the uterine endometrial cavity. MRI was performed. A 5.9 × 5.1 × 4.8 cm submucosal mass filled up the endometrial cavity. Hysterocopy examination confirmed the protruding mass at the lower portion of the endometrial cavity. The frozen section of the hysteroscopy was reported as malignancy. Subsequently, the patient underwent laparoscopic hysterectomy with bilateral salpingo-oophorectomy and bilateral pelvic lymph node dissection. There was no cancerous involvement in 19 dissected lymph nodes. The results of immunohistochemical stainings were positive for vimentin and CD56, a few positive for CD68, and negative for smooth muscle actin, desmin, CD10, CD34, pan-cytokeratin, HMB-45, S-100 protein, chromogranins and synaptophysin. Based on these histomorphologic findings, the diagnosis of UES was made. The patient was referred to an oncological center for chemotherapy and radiation therapy. Conclusion: It is important to establish a proper classification of endometrial stromal tumors by cytologic and immunohistochemical findings becase of different clinical course and prognosis.
( Hyun Kuk Kim ),( Young Joon Hong ),( Myung Ho Jeong ),( Weon Kim ),( Sung Soo Kim ),( Jum Suk Ko ),( Min Goo Lee ),( Doo Sun Sim ),( Keun Ho Park ),( Nam Sik Yoon ),( Hyun Ju Yoon ),( Kye Hun Kim ) 대한내과학회 2011 The Korean Journal of Internal Medicine Vol.26 No.1
Background/Aims: Carvedilol is an antioxidant that inhibits smooth muscle cell proliferation and migration. The aim of this study was to investigate the beneficial effects of carvedilol-loaded stents on 2-year clinical outcomes after stent implantation in patients with coronary artery disease. Methods: We performed a prospective trial with male subjects to compare the safety and effects of carvedilolloaded BiodivYsio(R) stents implanted into 20 patients with those of bare-metal BiodivYsio(R) stents implanted into 21 patients for de novo coronary lesions. The primary end point was the degree of neointimal hyperplasia, which was measured by intravascular ultrasound (IVUS) 6 months after the procedure; the secondary end point was major adverse cardiac events (MACE) at 2 years after implantation. All carvedilol and control stents were deployed successfully. Results: A 2-year follow-up was completed for 19 patients (95%) in the carvedilol stent group and 20 patients (95%) in the control stent group. IVUS showed a trend toward a larger luminal area (6.86 ± 2.59 vs. 5.47 ± 1.52 mm2, p = 0.267), smaller neointimal area (1.34 ± 0.70 vs. 2.40 ± 1.73 mm2, p = 0.18), and reduced net decrease in luminal area (-0.78 ± 0.97 vs. -1.89 ± 1.78 mm2, p = 0.106) in the carvedilol stent group compared with the control stent group, respectively. There were no significant differences in the incidence of MACE (10.5 vs. 30.0%, respectively, p = 0.132) between the groups at 2 years after stent implantation. Stent thrombosis did not occur in either group after 2 years. Conclusions: The carvedilol-loaded stents tended to inhibit neointimal hyperplasia without the occurrence of cardiac death, myocardial infarction, or stent thrombosis at 2-year follow-up. (Korean J Intern Med 2011;26:41- 46)